Next Article in Journal
Fusion Protein Vaccine Based on Ag85B and STEAP1 Induces a Protective Immune Response against Prostate Cancer
Previous Article in Journal
Targeting Haemagglutinin Antigen of Avian Influenza Virus to Chicken Immune Cell Receptors Dec205 and CD11c Induces Differential Immune-Potentiating Responses
 
 
Article

COVID-19 Vaccine mRNABNT162b2 Elicits Human Antibody Response in Milk of Breastfeeding Women

1
Department of Neurosciences, Reproductive Science and Dentistry, University of Naples “Federico II”, 80131 Naples, Italy
2
Department of Translational Medical Sciences, University of Naples “Federico II”, 80131 Naples, Italy
3
Department of Public Health, University of Naples “Federico II”, 80131 Naples, Italy
4
Department of Mother and Child, University Hospital Federico II, 80131 Naples, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Seth Pincus
Vaccines 2021, 9(7), 785; https://doi.org/10.3390/vaccines9070785
Received: 28 May 2021 / Revised: 6 July 2021 / Accepted: 12 July 2021 / Published: 13 July 2021
(This article belongs to the Section COVID-19 Vaccines and Vaccination)
Objective: The objective of this research is to demonstrate the release of SARS-CoV-2 Spike (S) antibodies in human milk samples obtained by patients who have been vaccinated with mRNABNT162b2 vaccine. Methods: Milk and serum samples were collected in 10 volunteers 20 days after the first dose and 7 seven days after the second dose of the mRNABNT162b2 vaccine. Anti-SARS-CoV-2 S antibodies were measured by the Elecsys® Anti-SARS-CoV-2 S ECLIA assay (Roche Diagnostics AG, Rotkreuz, Switzerland), a quantitative electrochemiluminescence immunometric method. Results: At first sample, anti-SARS-CoV-2 S antibodies were detected in all serum samples (103.9 ± 54.9 U/mL) and only in two (40%) milk samples with a low concentration (1.2 ± 0.3 U/mL). At the second sample, collected 7 days after the second dose, anti-SARS-CoV-2 S antibodies were detected in all serum samples (3875.7 ± 3504.6 UI/mL) and in all milk samples (41.5 ± 47.5 UI/mL). No correlation was found between the level of serum and milk antibodies; the milk antibodies/serum antibodies ratio was on average 2% (range: 0.2–8.4%). Conclusion: We demonstrated a release of anti-SARS-CoV-2 S antibodies in the breast milk of women vaccinated with mRNABNT162b2. Vaccinating breastfeeding women could be a strategy to protect their infants from COVID-19 infection. View Full-Text
Keywords: vaccine; milk; immunoglobulins; SARS-Cov-2 vaccine; milk; immunoglobulins; SARS-Cov-2
Show Figures

Figure 1

MDPI and ACS Style

Guida, M.; Terracciano, D.; Cennamo, M.; Aiello, F.; La Civita, E.; Esposito, G.; Gargiulo, V.; Maruotti, G.M.; Portella, G.; Sarno, L. COVID-19 Vaccine mRNABNT162b2 Elicits Human Antibody Response in Milk of Breastfeeding Women. Vaccines 2021, 9, 785. https://doi.org/10.3390/vaccines9070785

AMA Style

Guida M, Terracciano D, Cennamo M, Aiello F, La Civita E, Esposito G, Gargiulo V, Maruotti GM, Portella G, Sarno L. COVID-19 Vaccine mRNABNT162b2 Elicits Human Antibody Response in Milk of Breastfeeding Women. Vaccines. 2021; 9(7):785. https://doi.org/10.3390/vaccines9070785

Chicago/Turabian Style

Guida, Maurizio, Daniela Terracciano, Michele Cennamo, Federica Aiello, Evelina La Civita, Gennaro Esposito, Valentina Gargiulo, Giuseppe M. Maruotti, Giuseppe Portella, and Laura Sarno. 2021. "COVID-19 Vaccine mRNABNT162b2 Elicits Human Antibody Response in Milk of Breastfeeding Women" Vaccines 9, no. 7: 785. https://doi.org/10.3390/vaccines9070785

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop